HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon

Table 1 Demographic and clinical data of patients

Total number of patients	101
Sex distribution	55.4% (56/101) male
Median age [IQR]	34 [10–41] years
Median CD4 [IQR]	129 [29–466] cells/μl
Median viral load [IQR]	71,630 [19,041-368,000] copies/ml
ART regimens received by each group of patients, in addition to 3TC plus EFV or NVP
Group-A (n = 55)	both AZT and D4T
Group-B (n = 22)	TDF + “D4T or AZT”
Group-C (n = 24)	D4T (i.e. Triomune)

Legend. 3TC Lamivudine, EFV Efavirenz, NVP Nevrapine, ART antiretroviral therapy, AZT Zidovudine, D4T Stavudine, TDF Tenofovir, Triomune D4T + 3TC + NVP. All patients had received 3TC plus EFV or NVP. Footnote: Prior exposure to D4T and AZT was not concomitant

ISSN: 1471-2334